Table 4.
Treatment strategies, HIV status and outcomes of Leishmanial uveitis
| Reference | n | HIV | Vision at first presentation (logMAR) | Treatment | Visual outcome Outcome (logMAR) | ||
|---|---|---|---|---|---|---|---|
| 1st presentation | 2nd presentation | 3rd presentation | |||||
| Fox-Lewis et al.[48] | 1 | -ve | NA | B | - | - | Bilateral blindness |
| Van Os et al.[49] | 1 | +ve | OD: 0.3 OS: 0.2 | A | A, D | D, H | OD: 0.7 OS: 0.22 |
| Perrin-Terrin et al.[38] | 1 | +ve | OD: counting fingers OS: 0.3 | A, D | A, B, D, F | - | OD: phthisis OS: 0 |
| Ramos et al.[50] | 1 | +ve | OS: field defect OD: full vision | F | - | - | Complete resolution |
| Meenken et al.[39] | 1 | +ve | Light perception | A, F, J | - | - | OD: finger counting OS: Enucleation |
| Salvanos et al.[35] | 1 | NA | OD: 0 OS: 0.2 | A, C | A, C, E | OD: 0.52 OS: light perception | |
| Gontijo et al.[52] | 1 | -ve | NA | A, D | A, F | - | OD: hand movements OS: 0.22 |
| Reinecke et al.[41] | 1 | -ve | NA | A | NA | - | Bilateral enucleation |
| Ferrari et al.[51] | 1 | -ve | 1 bilaterally | A, B, C, E, F | 1 bilaterally | ||
| Uveitis associated with HAART Induced Immune Reconstitution syndrome (IRIS) | |||||||
| Blanche et al.[46] | 1 | +ve | NA | A | E | - | OD: enucleation OS: full resolution |
| Davies et al.[59] | 1 | +ve | Full vision bilaterally | A | - | - | Resolution |
| Couture et al.[40] | 1 | +ve | Counting fingers bilaterally | A, C, G | - | - | OD: counting fingers OS: 0.18 |
| Reference | n | HIV | Vision at first presentation (logMAR) | Treatment | Visual outcome Outcome (logMAR) | ||
| 1st presentation | 2nd presentation | 3rd presentation | |||||
| Uveitis following systemic antileishmanial tderapy | |||||||
| Dechant et al.[37] | 3 | NA | OD: counting fingers OS: hand movements | A, C | A, C, F | - | OD: 1 OS: 1.78 |
| OD: 1 OS: 0.78 | A, C | - | - | Resolution | |||
| NA | F | A | - | Resolution | |||
| Bouomrani et al.[44] | 1 | -ve | 0.3 bilaterally | A | - | - | 0.1 bilaterally |
| Khalil et al.[43] | 5 | NA | NA | Nil | - | - | Bilateral blindness |
| Nil | - | - | Bilateral blindness | ||||
| A, F | - | - | Full resolution | ||||
| A, F | - | - | Full resolution | ||||
| A, F | - | - | Full resolution | ||||
| El-Hassan et al.[36] | 2 | NA | Counting fingers | A, F | - | - | Full resolution |
| Counting fingers | A, F | - | - | Lost to follow-up | |||
| El-Hassan et al.[42] | 2 | NA | 1.08 bilaterally | A, F | - | - | OD: 0 OS: 0.18 |
| 1.08 bilaterally | A, F | - | - | Full resolution | |||
| Sinha et al.[45] | 1 | -ve | Full vision bilaterally | A | A | A | Full resolution bilaterally |
n=number of patients; A=topical steroids; B=intra-ocular/sub-conjunctival steroids; C=systemic steroids; D=intra-ocular Amphotericin B; E=systemic amphotericin B; F=systemic antimonial; G=systemic miltefosine; H=pentamidine; J=systemic fluconazole; NA=not available